Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingqin Li

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Theranostics|September 1, 2020
Plasma protein-based signature predicts distant metastasis and induction chemotherapy benefit in Nasopharyngeal CarcinomaYelin Liang, Junyan Li, Qian Li, et al.
Journal for Immunotherapy of Cancer|July 22, 2020
Prognostic value of immune score in nasopharyngeal carcinoma using digital pathologyYa-Qin Wang, Lei Chen, Yan-Ping Mao, et al.
Cancer Communications (London, England)|November 2, 2018
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation StudyQiuyan Chen, Linquan Tang, Na Liu, et al.
Nature Cancer|April 15, 2026
Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapyYingqin Li, Dongxue Wang, Chunxian Ou, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Theranostics|September 1, 2020
Plasma protein-based signature predicts distant metastasis and induction chemotherapy benefit in Nasopharyngeal CarcinomaYelin Liang, Junyan Li, Qian Li, et al.
Journal for Immunotherapy of Cancer|July 22, 2020
Prognostic value of immune score in nasopharyngeal carcinoma using digital pathologyYa-Qin Wang, Lei Chen, Yan-Ping Mao, et al.
Cancer Communications (London, England)|November 2, 2018
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation StudyQiuyan Chen, Linquan Tang, Na Liu, et al.
Nature Cancer|April 15, 2026
Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapyYingqin Li, Dongxue Wang, Chunxian Ou, et al.
Pageof 5